-
Je něco špatně v tomto záznamu ?
Interferon Beta-1a versus Glatiramer Acetate: Changes of Innate Immunity in a Group of Women with Multiple Sclerosis
M. Peterka, M. Valis, O. Soucek, J. Krejsek, L. Sobisek, I. Sejkorova, B. Klimova, P. Stourac, Z. Pavelek, M. Novotny
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
37473734
DOI
10.1159/000532022
Knihovny.cz E-zdroje
- MeSH
- glatiramer acetát terapeutické užití MeSH
- interferon beta 1a terapeutické užití MeSH
- interferon beta terapeutické užití MeSH
- lidé MeSH
- peptidy terapeutické užití MeSH
- přirozená imunita MeSH
- relabující-remitující roztroušená skleróza * farmakoterapie patologie MeSH
- roztroušená skleróza * farmakoterapie MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
INTRODUCTION: Multiple sclerosis (MS) is a chronic inflammatory autoimmune demyelinating disease that secondarily leads to axonal loss and associated brain atrophy. Disease-modifying drugs (DMDs) have previously been studied for their ability to affect specific immunity. This study investigates the effect of interferon beta-1a (INF) and glatiramer acetate (GA) administration on changes in innate immunity cell populations. METHODS: Sixty Caucasian female patients with relapsing-remitting MS undergo blood sample testing for 15 blood parameters at baseline, 1 month, 3 months, and 6 months after treatment by GA or IFN (started as their first-line DMD). RESULTS: A statistically significant difference in the change after 6 months was found in the parameter monocytes (relative count) in the group of patients treated with IFN. The median increase was 27.8%. Changes in many of the other 15 parameters studied were 10-20%. CONCLUSION: Innate immunity has long been neglected in MS immunopathology. The findings suggest that IFN treatment may modulate the immune response in MS by affecting monocyte function and may provide insight into the mechanisms of action of IFN in MS.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24001316
- 003
- CZ-PrNML
- 005
- 20240213094538.0
- 007
- ta
- 008
- 240109s2023 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1159/000532022 $2 doi
- 035 __
- $a (PubMed)37473734
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Peterka, Marek $u Department of Neurology, Faculty of Medicine and University Hospital Plzen, Charles University in Prague, Plzen, Czechia
- 245 10
- $a Interferon Beta-1a versus Glatiramer Acetate: Changes of Innate Immunity in a Group of Women with Multiple Sclerosis / $c M. Peterka, M. Valis, O. Soucek, J. Krejsek, L. Sobisek, I. Sejkorova, B. Klimova, P. Stourac, Z. Pavelek, M. Novotny
- 520 9_
- $a INTRODUCTION: Multiple sclerosis (MS) is a chronic inflammatory autoimmune demyelinating disease that secondarily leads to axonal loss and associated brain atrophy. Disease-modifying drugs (DMDs) have previously been studied for their ability to affect specific immunity. This study investigates the effect of interferon beta-1a (INF) and glatiramer acetate (GA) administration on changes in innate immunity cell populations. METHODS: Sixty Caucasian female patients with relapsing-remitting MS undergo blood sample testing for 15 blood parameters at baseline, 1 month, 3 months, and 6 months after treatment by GA or IFN (started as their first-line DMD). RESULTS: A statistically significant difference in the change after 6 months was found in the parameter monocytes (relative count) in the group of patients treated with IFN. The median increase was 27.8%. Changes in many of the other 15 parameters studied were 10-20%. CONCLUSION: Innate immunity has long been neglected in MS immunopathology. The findings suggest that IFN treatment may modulate the immune response in MS by affecting monocyte function and may provide insight into the mechanisms of action of IFN in MS.
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a glatiramer acetát $x terapeutické užití $7 D000068717
- 650 _2
- $a interferon beta 1a $x terapeutické užití $7 D000068556
- 650 12
- $a roztroušená skleróza $x farmakoterapie $7 D009103
- 650 _2
- $a interferon beta $x terapeutické užití $7 D016899
- 650 _2
- $a peptidy $x terapeutické užití $7 D010455
- 650 12
- $a relabující-remitující roztroušená skleróza $x farmakoterapie $x patologie $7 D020529
- 650 _2
- $a přirozená imunita $7 D007113
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Valis, Martin $u Department of Neurology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czechia
- 700 1_
- $a Soucek, Ondrej $u Department of Clinical Immunology and Allergology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czechia
- 700 1_
- $a Krejsek, Jan $u Department of Clinical Immunology and Allergology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czechia
- 700 1_
- $a Sobisek, Lukáš $u Department of Neurology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czechia
- 700 1_
- $a Sejkorova, Ilona $u Department of Clinical Immunology and Allergology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czechia
- 700 1_
- $a Klimova, Blanka $u Department of Neurology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czechia
- 700 1_
- $a Stourac, Pavel $u Department of Neurology, Masaryk University, Faculty of Medicine and University Brno, Brno, Czechia
- 700 1_
- $a Pavelek, Zbysek $u Department of Neurology, Faculty of Medicine and University Hospital Plzen, Charles University in Prague, Plzen, Czechia
- 700 1_
- $a Novotny, Michal $u Department of Neurology, Charles University, Faculty of Medicine and University Hospital Hradec Kralove, Hradec Kralove, Czechia
- 773 0_
- $w MED00001655 $t European neurology $x 1421-9913 $g Roč. 86, č. 5 (2023), s. 334-340
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37473734 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240109 $b ABA008
- 991 __
- $a 20240213094535 $b ABA008
- 999 __
- $a ok $b bmc $g 2049757 $s 1211010
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 86 $c 5 $d 334-340 $e 20230720 $i 1421-9913 $m European neurology $n Eur Neurol $x MED00001655
- LZP __
- $a Pubmed-20240109